Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Howarth who wrote (628)	11/6/1999 5:01:00 PM
From: blankmind	Read Replies (2) \| Respond to of 10345

i will assume you are trying for the alz info from the front page. it did work for me last night and still works today. an interesting part of the alz press release from eln, and it is old, form july 99, "Should AN-1792 prove as successful in future human clinical trials as it has been in our preclinical mouse studies, we believe it will help treat a disease that devastates millions of patients and their families," he added and from the research overview: Conclusions These results confirm the hypothesis that amyloid plaque formation in these mice is a dynamic process involving both deposition and clearance. AN-1792 demonstrates that amyloid plaque deposition can be altered in these mice presumably by accelerating the clearance of amyloid plaque. These results raise the possibility of immunization with AN-1792 as both a treatment and perhaps a prophylactic measure against AD. Approval to commence Phase I clinical studies to assess the safety in AD patients with AN-1792 will be sought later in the year through the submission of an investigational new drug application with the U.S. Food and Drug Administration.